Neurology in California

Dongguan Quanding Medical Supplies Co., Ltd. is an OEM/ODM manufacturer headquartered in Shenzhen (established 2008) specializing in medical electrode pads, surgical management consumables, and monitoring system accessories. The company manufactures and distributes across three primary product families: pain management electrodes (TENS pads), patient monitoring electrodes (ECG/EEG), and surgical/electrosurgical accessories (grounding pads, neutral electrodes, patient return pads). Product portfolio includes TENS replacement electrode pads for lower back and muscle pain relief, disposable ECG electrodes in multiple sizes and substrate materials (foam, non-woven fabric), electrosurgical grounding plates and pads for adult and infant use, and medical lead connection wires for high-frequency surgery. The company reports 17+ years of R&D experience, 200+ product categories, and 500+ distribution partners with 99% customer satisfaction. Manufacturing capabilities include design, mold fabrication, sample confirmation, production, strict QC inspection, and after-sale service. Certifications include ISO 9001, ISO 14001, ISO 18001, CE, and API standards. Primary markets are OEM/ODM partners and medical device distributors. No FDA 510(k) clearance mentioned on site.

Persyst Development LLC is the worldwide leader in EEG (electroencephalography) software for clinical neurodiagnostics. The company develops and markets Persyst 15 (P15), a comprehensive Computer Assisted Review of EEG (C.A.R.E) platform that provides advanced tools for EEG data review, analysis, and monitoring. Core capabilities include automated seizure detection, spike detection, artifact reduction, and EEG trending analytics designed to support both high-volume institutions and community clinics. Persyst's seizure detection algorithm has been validated in peer-reviewed literature (Journal of Clinical Neurophysiology) as statistically noninferior to skilled human reviewers. The company also offers Persyst Mobile, the first FDA-cleared EEG monitoring and review application for mobile devices, enabling remote access to EEG data. Persyst is integrated with and sold/supported by every major EEG hardware manufacturer, including Micromed, Natus, Nihon Kohden, Cadwell, and Compumedics. The software is recognized as the standard of care, with adoption at 211 of 233 US News-ranked neurology and neurosurgery centers. The company maintains a strong commitment to clinical research and scientific validation, publishing findings in peer-reviewed journals and hosting educational events such as Persyst Grand Rounds.

huMannity Medtec

huMannity Medtec is a non-profit medical research and development organization based in Santa Clarita, California. Founded in 1985 by Alfred E. Mann, the organization focuses on creating innovative medical technologies to meet the needs of patients with limited treatment options. Rebranded in September 2023, huMannity Medtec is dedicated to addressing challenging healthcare issues through its research and development efforts. The organization specializes in implantable devices, drug delivery systems, and neuromodulation technologies. Its notable products include cochlear implants, insulin pumps, and retinal prosthetics. Over the years, huMannity Medtec has successfully launched several spinoff companies that have collectively achieved around $8 billion in market value. The organization also offers comprehensive development services, including concept development, prototyping, clinical trials, and commercialization partnerships, ensuring a robust pathway from innovation to market readiness.

ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. is a global medical technology company focused on navigation and delivery solutions for the brain and spine. Founded in 1994, it has become a leader in minimally invasive neurosurgery, providing the ClearPoint® System, which enables precise instrument navigation and therapeutic delivery for various neurological conditions. The company emphasizes real-time imaging and patient comfort, aiming to improve the quality of life for patients with complex neurological disorders. Headquartered in Solana Beach, California, ClearPoint operates a Global Training & Innovation Center and collaborates with over 90 neurosurgery centers worldwide. It supports more than 7,000 procedures and partners with over 60 organizations in biologics and drug delivery. ClearPoint offers a comprehensive platform that includes clinical solutions, biologics and drug delivery services, research collaboration opportunities, and training for healthcare professionals. Its integrated approach combines hardware, software, and real-time MRI-guided workflows to enhance the effectiveness of neurosurgical interventions.

Medeia Inc is a manufacturer and distributor of neurodiagnostic and cardiovascular physiological monitoring systems. Founded in 1992, the company specializes in state-of-the-art biometric hardware and software for autonomic nervous system assessment, vascular analysis, EEG/EEG-derived diagnostics, and sleep studies. Medeia's product portfolio serves neurologists, cardiologists, primary care physicians, and research institutions with comprehensive tools for objective physiological measurement, including autonomic function testing (ANS), pulse wave velocity analysis, peripheral neuropathy assessment, and neuroencephalography. The VitalScan product line addresses autonomic and vascular diagnostics; BrainView systems provide EEG and cognitive assessment; NeuroTrace offers ambulatory wireless EEG; SleepStudy delivers polysomnography; and CardioView supplies mobile cardiac telemetry. Products are designed for clinical workflow efficiency and are distributed internationally to healthcare providers and research facilities.

LVIS Corporation is a San Francisco Bay Area–based medical technology company specializing in neural information analysis and EEG diagnostics software. The company develops patented brain-imaging visualization and analysis technologies that decode brain network activity to support neurological disease diagnosis and clinical workflows. LVIS's flagship product is NeuroMatch®, a cloud-based SaaS platform that automates and enhances EEG examination, source localization, and 3D/4D brain visualization. NeuroMatch has received FDA 510(k) clearance (K250239) in the United States and MFDS regulatory clearance in South Korea. The platform addresses critical gaps in neurological healthcare capacity: the shortage of neurologists (1 per 23,259 people), sub-optimal clinical workflows, and surging demand for neurological diagnosis. LVIS is backed by prestigious academic partnerships, including Stanford Byers Center for Biodesign Faculty Fellowship, Stanford StartX incubator, and NVIDIA Inception Program support. The company has received research grants from the Stanford Spectrum Center, LivaNova, and the Epilepsy Foundation. Leadership includes neuroscience and engineering experts; the company was founded by Jin Hyung Lee, PhD. NeuroMatch was named a 2026 Edison Awards finalist. The company operates with headquarters in Palo Alto, California, and additional offices in Gangnam and Daegu, South Korea, serving both US and international markets.

Ceribell develops point-of-care EEG systems for rapid seizure detection and monitoring in critical care settings. The company's flagship product, a portable EEG platform integrated with the CLARITY® AI algorithm, enables bedside detection of seizure activity, including non-convulsive seizures, in ICUs, emergency departments, and neurology units. CLARITY® is FDA-cleared for pediatric and neonatal patients, representing the first and only FDA-cleared seizure detection algorithm for newborns preterm and up. The system delivers 95% sensitivity and 97% specificity for status epilepticus detection with 99.9% negative predictive value. Ceribell's secure cloud portal features FedRAMP High cybersecurity authorization for telemedicine consultation and remote EEG interpretation. Clinical evidence demonstrates the platform is associated with 4.1-day shorter median ICU stays and improved neurological outcomes compared to conventional EEG workflows. The company supports hospitals with ongoing in-person and virtual training. Target markets include intensive care units, emergency departments, and neurology departments in acute-care hospitals. Ceribell holds multiple FDA clearances (510(k)), CE mark certification, and has published 45+ peer-reviewed publications validating diagnostic accuracy and clinical utility in critical care populations.

Vielight Inc manufactures photobiomodulation (PBM) devices for consumer and clinical use, specializing in transcranial and intranasal light therapy systems targeting brain health and systemic wellness. The company's core technology uses safe, non-ionizing red and near-infrared light energy to stimulate mitochondrial ATP production, with applications in cognitive enhancement, neurological conditions, and immune support. Product lines include the Neuro series (Pro 2, Duo, Gamma, Alpha variants) for brain photobiomodulation targeting Alzheimer's disease, traumatic brain injury, Parkinson's disease, mild cognitive impairment, autism, and PTSD; the Vagus device for non-invasive vagal nerve stimulation; the MIP for systemic wellness and immunity; and the X-Plus for thymus stimulation. Vielight has published 30+ peer-reviewed studies in collaboration with leading institutions including UCSF, Harvard, University of Toronto, Boston University, and University of Utah, with 20+ ongoing clinical trials and 800+ research participants. The company holds Health Canada medical device approval and conducts FDA-regulated clinical studies. Devices are marketed directly to consumers, practitioners, athletes, and military/veteran populations. Manufacturing and logistics are based in Hayward, California; administration in Toronto, Ontario; and a USA sales office in Shepherdstown, West Virginia. Over 100,000 devices sold globally with a 4.8/5 customer rating.

MaxMoreSpine designs and distributes minimally invasive endoscopic spine surgery systems for the treatment of degenerative spinal disorders, lumbar disc herniation, and facet joint pathology. The company manufactures a portfolio of transforaminal, interlaminar, intradiscal, and cervical endoscopic systems that enable surgeons to perform spinal procedures using local anesthesia with reduced instrumentation, lower disposable costs, and improved patient safety compared to traditional open surgery. Primary product lines include the PTED Endoscopic System (percutaneous transforaminal endoscopic decompression), PSLD Endoscopic System (posterior interlaminar lumbar decompression), MaxFusion by Dr. Morgenstern (endoscopic transforaminal lumbar interbody fusion), Biportal Endoscopic System, J@blation System (facet joint ablation), and cervical mini systems. MaxMoreSpine serves orthopedic and neurosurgeons, pain management physicians, and hospitals globally. The company actively supports continued medical education through hands-on workshops, cadaveric training programs, and participation in international conferences. Products feature 4K visualization capabilities and neurological safety monitoring. Based in San Diego, California, MaxMoreSpine maintains European operations and distributes systems internationally.

Boston Scientific Corporation is a global medical device manufacturer serving multiple clinical specialties including cardiology, urology, gastroenterology, interventional radiology, electrophysiology, neurology, pain management, vascular surgery, and structural heart disease. The company manufactures and distributes a broad portfolio of minimally invasive medical devices, including cardiac rhythm management systems, interventional cardiology devices, electrophysiology catheters and mapping systems, spinal cord stimulation systems for pain management, urological devices, endoscopy and visualization systems, defibrillators, and interventional oncology equipment. Boston Scientific operates a healthcare professional portal providing online training through EDUCARE, e-commerce ordering, reimbursement resources, and comprehensive customer support with specialty-specific representative contact networks. The organization serves hospitals, ambulatory surgery centers, and healthcare professionals across the United States through direct sales and support teams organized by medical specialty. Products undergo rigorous regulatory compliance (FDA 510(k), international certifications) and the company emphasizes quality assurance and product safety as core organizational values. Customer care is available via a dedicated U.S. customer service line, with extended business hours Monday–Friday.

Viseon, Inc. is a medical device manufacturer specializing in advanced digital visualization systems for minimally invasive neurosurgery, with particular focus on cranial and spinal procedures. The company's flagship product is MaxView®, a 4K video imaging platform designed to enhance surgical precision and safety in lateral and posterior spinal procedures. MaxView® is a towerless system that provides high-resolution 4K visualization with integrated video and still-image capture capabilities, enabling improved operative documentation, patient safety, and surgical education. The platform is positioned to support all minimally invasive spine procedures with a single integrated imaging solution. Viseon serves major academic medical centers and tertiary hospitals nationwide, with installations at prestigious institutions including Duke University Hospital, Cedars-Sinai, NYU Langone Health, Hospital for Special Surgery, and Naval Medical Center San Diego. The company's product line addresses the neurosurgery market segment, particularly spine and cranial surgery specialties where enhanced visualization directly impacts surgical outcomes and procedural efficiency. Viseon's technology emphasizes digital capture and recording capabilities for intraoperative content, supporting contemporary OR documentation requirements and surgeon training workflows.

ARK Diagnostics Inc is a clinical laboratory diagnostics company specializing in the design, development, and manufacture of in vitro diagnostic immunoassays for therapeutic drug monitoring (TDM) and urine drug testing (UDT). The company develops next-generation homogeneous enzyme immunoassays that are liquid, stable, and ready-to-use, with applications available for automated clinical chemistry systems. ARK's product portfolio spans multiple therapeutic categories: epilepsy antiepileptic drug monitoring (gabapentin, lamotrigine, levetiracetam, topiramate, zonisamide, lacosamide, oxcarbazepine metabolite); cancer chemotherapy monitoring (methotrexate); anti-infective agents (linezolid, voriconazole); urine drug testing for substances including opioids, benzodiazepines, synthetic cannabinoids, ketamine, and ethyl glucuronide; and veterinary applications (cortisol, phenobarbital, progesterone, thyroxine, SDMA, gabapentin, levetiracetam, zonisamide). The company holds CE Mark approvals across multiple product lines and FDA clearances (510(k)) for epilepsy assays, cancer assays, and select UDT assays. Voriconazole II received FDA de novo approval. Several products are in development, including additional opioid assays, benzodiazepine formulations, antiretroviral monitoring, and oral anticoagulant assays. ARK serves clinical laboratories, hospital pathology departments, and forensic testing facilities through direct sales and international distributor networks. The company is ISO and GLP-compliant, with active participation in professional conferences (ADLM, IATDMCT, CAT).

Universal Brain Inc. develops a medical-grade EEG system designed for precision psychiatry, focusing on objective, brain-based diagnosis and treatment of psychiatric conditions, primarily depression. The company has engineered a next-generation EEG wearable headset that captures event-related potentials (ERPs)—brain responses to cognitive and emotional stimuli—and pairs it with Neurotique™, a proprietary digital interface and AI-driven software algorithm that translates raw EEG data into actionable clinical insights. The platform enables neurotyping: the classification of patients based on functional brain measures derived from EEG, allowing clinicians to identify subtypes of psychiatric disorders and tailor treatment accordingly. Universal Brain's approach addresses the heterogeneity of psychiatric conditions by examining core neural systems including attention, memory, and emotional processing. The system is currently investigational and intended for use in clinical settings to aid treatment decision-making and support psychiatric clinical drug trials. The company's leadership includes a psychiatrist founder/CEO (Kazu Okuda, M.D.) and Chief Scientist with expertise in clinical neuroscience (Greg Hajcak, Ph.D.), indicating strong research-clinical integration. The platform represents a shift toward objective, neurobiological markers rather than symptom-based diagnosis alone.

NeuraSignal is a medical technology company specializing in advanced transcranial Doppler (TCD) ultrasound systems enhanced through robotics, artificial intelligence, and cloud computing. Founded in 2013 and based in Los Angeles, the company develops FDA-cleared intelligent ultrasound platforms designed to automate and improve cerebral hemodynamics assessment for stroke detection, patent foramen ovale (PFO) screening, and vasospasm monitoring. The NG2 Intelligent Ultrasound system uses robotic control and machine learning algorithms to automatically locate the temporal window and lock onto cerebral blood flow signals with accuracy comparable to expert sonographers, while eliminating operator variability. The NeuraSignal Platform provides cloud connectivity enabling remote access, real-time data collaboration, and advanced analytics for clinical decision-making. Their portable Lucid™ TCD systems support both clinical deployment in hospital settings and international research initiatives. The technology is particularly valued in comprehensive stroke centers and neuroscience programs for its noninvasive nature, painless administration, and superior detection rates—clinical data demonstrates 3× shunt detection rates and 2.7× detection of intervenable shunts compared to standard transthoracic echocardiography (TTE).

Cala Health is a bioelectronic medicine company specializing in wearable neuromodulation therapies for chronic diseases. Founded in 2014 as a Stanford University spinout, Cala develops non-invasive peripheral nerve stimulation devices using transcutaneous afferent patterned stimulation (TAPS). The company's flagship product, the Cala kIQ, is an FDA-cleared wrist-worn device for reducing action hand tremor in essential tremor and Parkinson's disease patients. The Cala kIQ delivers on-demand TAPS therapy with clinically proven efficacy—patients report tremor reduction within 40 minutes, with relief lasting over 90 minutes post-session. The company supports a comprehensive patient lifecycle ecosystem including prescription fulfillment, insurance reimbursement assistance, connected care services via MyCala.com patient portal, telemedicine consultation, and medication management support. Medicare and VA coverage are available for qualifying beneficiaries. Cala Health is expanding its therapeutic focus to neurology, cardiology, and psychiatry applications.

NeurOptics is a worldwide leader in pupillometry technology for critical care, neurology, neurosurgery, emergency medicine, and applied research. The company develops and markets the NPi-300 Pupillometer, a handheld device that provides objective, quantitative assessment of pupil size and reactivity independent of examiner variability. The NPi-300 is adopted in over 1,000 U.S. hospitals and represented in more than 50 countries globally. The device measures pupillary responses and constriction velocity, enabling clinicians to detect subtle changes in pupillary response that may indicate increased intracranial pressure, neurological decline, or brain injury—particularly valuable in sedated or comatose patients where subjective penlight examination is unreliable. NeurOptics also provides pupillometry instrumentation for applied research applications, supporting both human and animal research across various clinical and research settings. The company emphasizes device integration with electronic medical records (EMR) to streamline clinical workflows and enable trend analysis of pupillary data as a vital sign. The NPi-300 is used extensively in neurocritical care units, stroke services, trauma centers, and cardiac arrest care settings. Clinical evidence supports the device in management of traumatic brain injury, cardiac arrest, malignant cerebral edema, and assessment for brain death determination.

Diagnostic BioSystems Inc., founded in 1994, is a Pleasanton, California-based manufacturer of immunohistochemistry (IHC) reagents and anatomic pathology products for diagnostic and research applications. The company specializes in primary antibodies (IVD and RUO formulations for U.S. and international markets), detection systems (UnoVue™ HRP, PolyVue™ Plus HRP/DAB, Mohs™ HRP), chromogens, ancillary reagents (blockers, mounting media, buffers), and antigen retrieval solutions. DBS manufactures two proprietary automated staining instruments: the DBS HighLighter™ 360 autostainer (fully automated slide staining system) and Montage Opus365™ (antigen retrieval system). The product portfolio includes fluorescent antibodies (FITC, CF488), special stains, and accessory reagents for pathology labs. Recent product launches feature cancer-specific antibodies (CEACAM5, Uroplakin 3B, Claudin 18.2, NUT1, EGFR, CD117/c-kit, PSA). The company markets products both under IVD (in vitro diagnostic) and RUO (research use only) designations, with distribution through partnerships including Cardinal Health Scientific and ThermoFisher in the USA. DBS maintains regulatory compliance with FDA and international requirements (CE, SFDA approvals noted). The company serves anatomic pathology laboratories, cancer research institutions, and clinical diagnostic centers globally through direct sales and international distributor networks.

BIO PROTECH, INC. is a medical device manufacturer specializing in surgical instrumentation, patient monitoring electrodes, and therapeutic devices for intraoperative and diagnostic applications. The company produces surgical smoke evacuation systems including smoke pencils (telescopic, economy, dual extension), surgical pencils, smoke adapters, and laparoscopic accessories, along with electrosurgical unit (ESU) plates. In cardiology, BIO PROTECH manufactures ECG electrodes, TAB electrodes, neonatal electrodes, and SpO2 sensors for patient monitoring. The neurology product line includes EMG needles and electrodes, EEG cup electrodes, surface electrodes, intraoperative neuromonitoring (IONM) needles, and neurology cables. Pain management offerings encompass TENS (transcutaneous electrical nerve stimulation) electrodes and TENS units, as well as EMS (electrical muscle stimulation) and interferential (IF) therapy units. The company serves global markets with manufacturing and distribution capabilities, operating sales offices in both North America (Cerritos, CA) and South Korea, with support for Europe, Middle East, Asia, South America, Oceania, and Africa. Products are designed to meet global quality standards for surgical, diagnostic, and therapeutic applications across multiple medical specialties.

Vesalio, Inc is a medical device company specializing in mechanical thrombectomy systems for acute arterial occlusions across neurovascular, coronary, and peripheral vascular territories. The company manufactures a comprehensive platform of patented thrombectomy devices leveraging proprietary Drop Zone™ technology designed to maximize clot retention and first-pass recanalization success. Primary product lines include: NeVa (neurovascular stroke thrombectomy), NeVa NET (next-generation neurovascular system with integrated micro-filter), NeVa VS (post-aneurysmal subarachnoid hemorrhage cerebral vasospasm treatment), enVast (coronary thrombectomy for large thrombus burden), pVasc (peripheral arterial occlusion thrombectomy), and NeVaSC (aspiration catheter). The company holds multiple regulatory clearances including FDA 510(k) clearances for several product lines and CE marks for international markets. Vesalio addresses a significant clinical need across three major disease areas: ischemic stroke (approximately 15 million cases annually, 80% clot-related), acute myocardial infarction (8.5 million cases annually, 30% clot-related), and acute limb ischemia (2.5 million cases annually, 80% clot-related). The platform is supported by robust clinical evidence, with published cases and peer-reviewed data demonstrating high recanalization rates and clinical efficacy across multiple vascular territories.

ECA Medical Instruments is a manufacturer of single-use, Surgery-Ready™ procedure kits and surgical instruments. The company specializes in pre-assembled, sterile surgical kits that serve as a single-source solution for hospitals and surgical centers, eliminating the need for on-site sterilization and calibration. ECA is recognized as an international authority on torque-limiting instrumentation, a critical capability in orthopedic and spine surgery where precise torque application prevents over-tightening of fasteners and implants. Product lines include orthopedic procedure kits, spine surgery kits (including cervical fusion kits), cardiovascular procedure kits, and neuromodulation instrumentation. All kits are supplied sterile and calibrated on-site before shipment, ensuring compliance with surgical standards and reducing preparation time in the operating room. The company serves market leaders in surgical hospitals, orthopedic centers, and specialty surgical facilities. ECA's manufacturing process integrates instrument sourcing, kit assembly, sterilization, and quality assurance, positioning the firm as a comprehensive vendor for surgical procedure kit solutions.

Ampa Health is a neurotechnology company developing transcranial magnetic stimulation (TMS) systems for treating depression, anxiety, PTSD, and other neurological and mental health disorders. The flagship Ampa One platform delivers accelerated TMS using Synchronized Neuromodulation Therapy (SNT), enabling significantly shorter treatment protocols—potentially one-day treatment—while maintaining clinical efficacy. Clinical data demonstrates 72% remission rates for depression within three months. The system is designed for clinical accessibility, portability, and scalability, with telemedicine capabilities for remote treatment delivery. Ampa targets healthcare providers and mental health facilities seeking evidence-based, efficient neuromodulation solutions to expand treatment capacity and improve patient access to care.

CGX, LLC is a global leader in mobile EEG technology, specializing in the design and manufacture of advanced dry EEG headsets for physiological data acquisition. The company develops state-of-the-art wearable biosignal acquisition systems featuring dry electrode technology, LED impedance indicators, and long battery life. Their flagship products—the Quick-32r (32-channel) and Quick-20r v2 (21-channel) headsets—are fully integrated with Brain Products' BrainVision Recorder software and are deployed across leading research institutions, including UCSD, University of Chicago, and major pharmaceutical companies. CGX systems are designed for ease of use, comfort, and signal quality in clinical research, sleep scoring, and neuroscience applications.

BioLegend is a biomedical research company specializing in the development and manufacturing of research reagents and antibodies for scientific investigations. The company operates a modern manufacturing facility in San Diego, California, and offers a comprehensive portfolio including monoclonal and polyclonal antibodies, immunoassay solutions, recombinant proteins, magnetic cell separation products, and single-cell proteogenomics reagents. BioLegend serves research institutions, pharmaceutical companies, and clinical laboratories across multiple therapeutic areas including neuroscience, oncology, immunology, stem cell research, and clinical diagnostics. The company has acquired the Covance antibody product portfolio to strengthen its neuroscience offerings and collaborates with leading research organizations such as The Michael J. Fox Foundation for Parkinson's Research and Illumina. BioLegend provides IVD (in vitro diagnostic) reagents and ASR (Analyte Specific Reagent) products for immunohistochemistry, immunophenotyping, and flow cytometry applications. The company emphasizes quality manufacturing, expert technical support, and custom product development services to support precision medicine, oncology, and biomedical discovery.

FluxWear, Inc. manufactures SHIFT, a wearable neuromodulation device designed for non-invasive pain management and mental health applications. SHIFT delivers low-level pulsing magnetic fields (PEMF technology) through microcoil emitters positioned in a comfortable, hat-like wearable form factor. The device operates at very low magnetic field intensities (earth-level) and delivers a 25-minute treatment session activated by a single button on a portable controller. Clinical applications include chemotherapy-induced peripheral neuropathy (CIPN), chronic pain reduction, anxiety management, focus improvement, and OCD symptom relief. Users report greater than 50% pain reduction with rapid onset (approximately 25 minutes). SHIFT is FDA Class I registered and employs proprietary pulse train and emitter sequencing algorithms for whole-brain stimulation without user-configurable settings. The device is available in multiple color options and is designed for home use and portability. FluxWear conducts clinical trials and has received recognition including NY Awards, Muse Awards, and an Innovator of the Year nomination from the Orange County Business Journal. The company was founded following the autoimmune condition diagnosis of co-founder Nadia in 2017.

Magnus Medical Inc.

Magnus Medical, Inc. is a medical device company based in Burlingame, California, specializing in therapeutic neuromodulation technology for neuropsychiatric disorders, particularly major depressive disorder (MDD). Founded by Dr. Brandon Bentzley, the company focuses on personalized, non-invasive brain stimulation to help those with treatment-resistant depression. Its core product, the SAINT® neuromodulation system, was developed from research at the Stanford Brain Stimulation Lab and received FDA Breakthrough Device Designation for MDD treatment. The SAINT system utilizes electromagnetic pulses for targeted brain stimulation, aiming to achieve remission in as few as five days. Magnus is actively conducting clinical trials to assess the system's effectiveness and has begun commercialization, with Medicare coverage starting in July 2024. The company has established partnerships with several healthcare institutions, including the University of Arkansas for Medical Sciences and MUSC Health, and is expanding its reach in hospital and outpatient settings.

Compumedics Limited is a world-leading designer and manufacturer of diagnostic and research technologies for sleep, neurodiagnostics, brain research, and ultrasonic blood flow monitoring. Founded in 1987 and listed on the Australian Securities Exchange (ASX: CMP) since 2000, the company has established itself as a primary supplier of polysomnography (PSG) systems, EEG amplifiers and recorders, and magnetoencephalography (MEG) equipment. The product portfolio includes comprehensive sleep diagnostics solutions spanning in-lab, home-based, ambulatory, and wireless configurations, as well as complete neurodiagnostic platforms supporting clinical EEG, long-term monitoring (LTM), ICU continuous EEG (cEEG), and high-channel-count research applications. The company offers proprietary software platforms—Profusion Sleep, Profusion EEG, Profusion neXus 360 for laboratory management, and CURRY for advanced brain analytics—alongside supporting accessories and consumables. Compumedics operates a global infrastructure with corporate headquarters in Abbotsford, Australia, and major regional hubs in Charlotte, North Carolina (USA), Dresden and Freiberg (Germany), Strasbourg (France), and Shenzhen (China). The company maintains over 15% investment in R&D and holds a Medical Advisory Board to ensure continued innovation. Products are distributed globally to clinical institutions, research centers, and pharmaceutical organizations conducting clinical trials. Regulatory credentials and specific certifications are not detailed in the accessible content, though the company's long operational history and ASX listing indicate substantial compliance infrastructure.

Neurolutions develops the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared brain-computer interface (BCI) device for home-based motor recovery therapy in chronic stroke survivors. The non-invasive system comprises an EEG headset that captures motor intention signals from the unimpaired brain hemisphere, a powered wireless handpiece that moves the affected hand, and a tablet interface for guided treatment and progress tracking. Clinical data shows approximately 70% of trial participants improved arm and hand function, with an average 8.1-point improvement on the Fugl-Meyer Assessment within 12 weeks. IpsiHand enables patients to overcome recovery plateaus years or decades post-stroke through autonomous home therapy, with broad insurance coverage including Medicare and VA benefits.

Noctrix Health, Inc. is a medical device company specializing in clinically validated wearable therapeutics for chronic neurological disorders. The company's flagship product is Nidra, a prescription-grade wearable device employing Tonic Motor Activation (TOMAC) therapy for the management of Restless Legs Syndrome (RLS). Noctrix received FDA Breakthrough Device Designation in June 2020 and obtained De Novo clearance in April 2023. The RESTFUL pivotal trial, published in dual feature in SLEEP journal (July 2023), demonstrated clinical efficacy. The company achieved first commercial shipment in July 2023. CMS issued dedicated HCPCS codes and reimbursement payment for Nidra therapy and supplies in October 2024. The company's leadership comprises medical device experts, neuroscientists, and consumer electronics engineers. Noctrix is backed by leading venture and angel investors. The product is indicated for patients with RLS and is positioned as a prescription-grade therapeutic with consumer-grade user experience. The device addresses a significant unmet need in chronic neurological disease management, with established reimbursement pathways and clinical practice guideline inclusion from the American Academy of Sleep Medicine (AASM).

DWL (Compumedics Germany GmbH), operating since 1991, is a specialized manufacturer of transcranial Doppler (TCD) ultrasound systems for real-time hemodynamic monitoring and vascular diagnostics. Core products include the EZ-Dop point-of-care diagnostic system, Multi-Dop T (EU MDR 2017/745 certified), DBX/DBX1, MDX series (color Doppler and CO2 reactivity), and the MDT multi-channel monitoring platform. The company designs portable baseline systems through comprehensive multimodal solutions supporting handheld probes, micro-probes, monitoring probes, probe fixation systems, and specialized analysis software including Neuro-Monitoring-Analyse with Z-Score waveform evaluation. Clinical applications span neurology, neuro/cardiac/vascular surgery, anesthesiology, critical care, emergency medicine, ENT, and maxillofacial surgery. Primary indications include stroke management, brain death diagnosis, vasospasm detection, PFO evaluation, sickle cell disease screening, and intraoperative neuromonitoring. Systems employ fully digital Doppler sonography with M-Mode capability. DWL maintains installations in 11,000+ hospitals and clinics across 120+ countries. Manufacturing and regulatory capabilities include EU MDR compliance and ISO certification. The company provides clinical software, training support at international conferences, and technical service.

BIOPAC Systems, Inc. designs and manufactures modular, integrated life science data acquisition and analysis systems for research, education, and human insights applications. The company specializes in high-fidelity measurement of physiological signals including electrocardiography (ECG), electroencephalography (EEG), electromyography (EMG), electrodermal activity (EDA), blood pressure, impedance cardiography, and specialized measures such as functional near-infrared spectroscopy (fNIRS) and laser Doppler flow. BIOPAC systems operate in laboratory, MRI, and real-world/field environments with both wired and wireless data logging capabilities. The company serves three primary markets: academic research (human and animal studies, neuroscience, cardiology, psychophysiology), educational institutions (undergraduate and graduate teaching labs across multiple disciplines), and commercial/human insights applications (consumer research, neuromarketing, product development). Products include the AcqKnowledge software platform for data acquisition and analysis, modular hardware units, and the Biopac Student Lab System with integrated curriculum. Systems support advanced signal processing including heart rate variability analysis, automated ECG/EEG/EMG analysis, event-related potentials (ERP), and cognitive state assessment. BIOPAC is cited in over 58,600 peer-reviewed studies. The company provides extensive support through technical specialists, knowledge bases, application notes, webinars, hands-on workshops, and user manuals for both proprietary and third-party hardware integration.

Cortigent, Inc. is a neuromodulation medical device company developing advanced brain implant systems for treating profound blindness and stroke-related paralysis. The company's core technology comprises a proprietary data processing unit that wirelessly controls microelectronic implants containing a unique 60-electrode array positioned on the brain's surface. These electrodes deliver targeted electrical stimulation to specific brain regions to either restore visual perception or enhance motor recovery. Orion® Visual Cortical Prosthesis System is Cortigent's lead product candidate, designed to provide artificial vision to patients with nearly all forms of profound blindness, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye trauma. The Orion system builds upon the legacy of Argus® Retinal Prosthesis System (Argus II), the world's first FDA-approved device for artificial vision in retinitis pigmentosa patients. Cortigent has discontinued Argus II to focus development on Orion, which targets a substantially larger patient population. A second development program addresses motor skill recovery in stroke patients. This neurostimulation system leverages the 60-channel electrode configuration to selectively target motor cortex neurons, intended to enhance hand and arm movement recovery in partially paralyzed stroke victims undergoing rehabilitation. As of January 2026, Cortigent presented promising six-year early feasibility study results for the Orion system at the North American Neuromodulation Society conference. The company is currently a subsidiary of Vivani Medical with active clinical studies recruiting prospective participants. All devices remain in clinical development or early-stage commercialization phases.

Composite Manufacturing, Inc. (CMI) is an FDA-registered manufacturer and biomedical engineering company specializing in advanced carbon fiber and composite medical device design and production. For over 40 years, CMI has engineered custom composite solutions for neurological surgery, interventional neuroradiology, orthopedic procedures, urological interventions, and general surgical practices. The company manufactures radiolucent patient positioning systems, surgical tables, and imaging-compatible equipment featuring carbon fiber composites that are up to 5x stronger than aluminum at a fraction of the weight. CMI provides end-to-end capabilities including in-house design, tooling, prototyping, and manufacturing with vertical integration ensuring superior quality control, cost efficiency, and rapid market response. Their proprietary technologies enable complex geometries and high-performance solutions for demanding medical, surgical, and imaging applications.

NeuroPace, Inc. is a neurotechnology company specializing in closed-loop neuromodulation therapy for drug-resistant epilepsy. The company manufactures and markets the RNS (Responsive Neurostimulation) System, an FDA-approved implantable device designed for adults with focal epilepsy who have failed treatment with two or more anti-seizure medications. The RNS System is the only FDA-approved epilepsy device that delivers personalized, responsive treatment by detecting abnormal brain activity via EEG monitoring and delivering targeted stimulation to interrupt seizures before they occur. The system provides real-time data collection and analysis, enabling physicians to optimize individual treatment plans based on each patient's unique seizure fingerprint and triggers. The company serves epileptologists, neurosurgeons, neurologists, and comprehensive epilepsy centers across the United States. The RNS System is indicated for patients 18 years and older with localized seizure foci (no more than two) and a minimum of three seizures per month. NeuroPace provides clinical support, patient education, and healthcare provider resources including the nSight cloud-based data platform and PDMS (Patient Data Management System) for remote monitoring and device programming. The company maintains regulatory compliance with FDA approval and conducts ongoing clinical research to support therapeutic outcomes.

EnlitenAI develops Neuroliten, an FDA-registered Class I Software as a Medical Device (SaMD) platform for decision support in the treatment of neurological and neurobehavioral disorders. The platform specializes in seizure management for drug-resistant epilepsy and is designed to support clinical decision-making for conditions including autism spectrum disorder, PTSD, anxiety, depression, and Parkinson's disease. The system integrates multimodal data streams from FDA-cleared wearables and implantables to deliver personalized, data-driven treatment recommendations and drug-device titration guidance. Neuroliten was registered with the FDA on January 9, 2026, under OUG product code classification. The company operates with a device-agnostic architecture that translates patient-specific data into actionable clinical insights, moving away from trial-and-error approaches in neurological care. EnlitenAI's team includes clinical expertise from UCSF Neurology, computational sciences specialists, and digital health entrepreneurs. The platform is designed for use by neurologists, patients, caregivers, and pharmaceutical partners. The company follows a phased regulatory strategy with additional functionalities under development for future submission. Based in Tracy, California, with a regional office in the greater Sacramento area, EnlitenAI focuses on precision neurological and neurobehavioral care delivery.

Q'Apel Medical Inc. is a neurovascular medical device manufacturer based in Fremont, California, specializing in innovative neurological catheters and access systems for stroke intervention and cerebral aneurysm treatment. Founded in 2015, the company designs advanced catheter technologies that enable therapeutic thrombectomy and neurovascular procedures with enhanced precision and patient outcomes. Q'Apel's product portfolio includes the Walrus Balloon Guide Catheter system, recognized as a leading variable-stiffness device for mechanical thrombectomy in the U.S. market; the Wahoo Control™ and Armadillo SelectFlex™ Neurovascular Access Systems, engineered for superior navigation and variable stiffness performance; and the recently FDA-cleared Zebra Neurovascular Access System. The company's devices are deployed across over 130 U.S. hospital systems and have treated more than 20,000 patients since 2019. Q'Apel is actively pursuing international expansion and continued innovation in endovascular access technology.

SUDOSCAN Inc. manufactures and distributes the SUDOSCAN device, a Class IIa medical device for early detection and monitoring of peripheral autonomic neuropathies and small fiber neuropathy. The device uses electrochemical skin conductance (ESC) measurement via electrode stimulation of sweat glands to assess sudomotor function and autonomic nerve fiber integrity. A non-invasive test completed in under 3 minutes with no patient preparation required, SUDOSCAN is indicated for diabetic neuropathy screening, chemotherapy-induced peripheral neuropathy (CIPN) monitoring, and evaluation of neuropathies associated with amyloidosis, Sjögren's syndrome, Fabry disease, Hepatitis C, and other neurological conditions. The device consists of a computer system with four electrodes where patients place hands and feet; results are automatically displayed as electrochemical skin conductance scores indicating presence and severity of autonomic dysfunction. Manufactured by parent company Impeto Medical SAS (France headquarters), SUDOSCAN has sold over 5,000 devices worldwide and is included in clinical guidelines from the European Network for TTR-FAP Amyloidosis, German diabetes management guidelines, and Latin American diabetes associations. CE-marked and FDA-cleared for use. The company also offers SudoCloud, a secure cloud-based remote patient monitoring platform for connecting, retrieving, and managing patient data. Clinical evidence includes 150+ peer-reviewed journal publications supporting reliability and diagnostic utility across multiple therapeutic areas.

Invenio Imaging, Inc. develops and commercializes the NIO Laser Imaging System, a stimulated Raman histology (SRH) platform that enables rapid, label-free tissue imaging for intraoperative pathology assessment. The NIO system delivers high-quality histological images in under 3 minutes without requiring tissue staining or sectioning, allowing on-site evaluation by surgical and pathology staff. The platform features the NIO Slide sample preparation module and integrates natively with existing hospital IT infrastructure via DICOM interfaces for digital image sharing and archiving. Invenio Imaging also offers NIO Glioma Reveal, a deep learning–based image analysis algorithm for identifying cancer infiltration in glioma surgery; this product has received CE Mark approval in the European Union and is available for research use only in the United States. The company serves multiple surgical specialties including neurosurgery, interventional pulmonology, urology, ENT, breast oncology, GI endoscopy, organ transplantation, and nephrology. The technology preserves tissue viability for downstream molecular and genetic analysis, enabling pathologists to conduct additional studies on the same specimen. The NIO platform has exceeded 2,000 installed systems globally and is supported by clinical evidence from leading academic medical centers including NYU Langone Health and University of Freiburg.

NeoLight, LLC manufactures specialized medical devices for neonatal intensive care, including brain monitoring, retinal imaging, phototherapy, and developmental support systems. The company's product portfolio addresses critical clinical needs in NICU environments: the nëo™ CFM with aEEG provides cerebral function monitoring to support decision-making in neurological assessment; the ICON™ retinal imaging system with patented Direct Illumination™ technology enables screening for retinopathy of prematurity and other ocular conditions; the Skylife™ Neonatal Phototherapy System delivers spectral power-optimized treatment for neonatal jaundice; and the P.A.L. (Pacifier-Activated Latch) device encourages non-nutritive sucking to promote oral feeding development in preterm and critically ill infants. NeoLight's devices are designed for use in tertiary and secondary neonatal care settings, emphasizing evidence-based clinical outcomes and user-centered design. The company positions itself as a neonatal innovation leader integrating advanced monitoring, diagnostic imaging, and therapeutic technologies to improve developmental outcomes and reduce NICU length of stay.

iMediSync is a South Korean digital mental health platform company specializing in AI-driven biomarker detection and analysis for brain and cardiac health. The company designs and manufactures proprietary dry-electrode wearable headsets for non-invasive measurement of brainwave (EEG) and heart rate variability (HRV) signals without gel or conductive pastes. iMediSync operates three primary product lines: iSyncWave (wireless dry-electrode EEG measurement headset with integrated care capabilities), iSyncBrain (cloud-based AI brainwave analytics software with quantitative EEG analysis and cognitive impairment screening), and iSyncHeart (cloud-based HRV analytics for stress, anxiety, and depression monitoring). The company has obtained regulatory clearance in South Korea (식약처 approval for both device and software), US FDA Class II clearance for iSyncWave, and FDA software device authorization for iSyncBrain. iMediSync maintains proprietary age- and gender-stratified EEG reference databases and employs machine learning models for automated noise removal, brain mapping, and clinical decision support. Applications span clinical neurology, psychiatry, occupational health screening, and research collaborations. The platform supports early detection of mild cognitive impairment and stress-related autonomic nervous system imbalance.

META Dynamic, Inc.

META Dynamic, Inc. is a surgical navigation support company based in Orange, California. Founded in 2002 by Tom Pfleider, the company specializes in outsourced surgical services and equipment support for image-guided surgery (IGS) procedures. With a focus on cranial, spine, and ENT surgeries, META Dynamic has supported over 50,000 surgical navigation procedures, celebrating its 40,000th surgery milestone in early 2025. The company offers a range of services, including its Outsourced Surgical Services™ program, which provides technical support and clinical consultation. The META GPS™ Protocol is a nationwide, system-agnostic support service available on-demand. Additionally, META Dynamic provides comprehensive surgical support, advanced planning, and equipment rentals for hospitals and surgical facilities. With a team of over 60 clinical specialists, the company ensures 24/7 availability to assist with IGS procedures, regardless of the navigation system used. Recognized as one of the top 30 fastest-growing companies in the US by Global Business Leaders Magazine, META Dynamic continues to expand its national footprint.

Evolution Devices, Inc. manufactures EvoWalk, an FDA-cleared wearable Functional Electrical Stimulation (FES) device designed to improve walking ability and mobility in patients with foot drop caused by neurological impairments. The device stimulates leg muscles (tibialis anterior, hamstring, and knee flexors/extensors) at precise moments during the gait cycle to enhance ankle dorsiflexion, reduce tripping, and increase overall gait stability. EvoWalk incorporates advanced AI algorithms that learn individual walking patterns and personalize stimulation delivery in real time. The system includes a slim, wearable controller and a companion mobile app for adjusting stimulation levels, setting therapy goals, and tracking mobility metrics including steps, speed, and distance. Clinical evidence shows users achieve approximately 30% more steps and 15% faster walking speed after three months of consistent use. Target patient populations include individuals with foot drop related to stroke, multiple sclerosis, traumatic brain injury, and spinal cord injury. The company operates a direct-to-consumer model with nationwide shipping, offers 30-day trial periods with 85% refund policy, and provides ongoing technical and clinical support at no additional cost beyond consumable electrodes. VA benefits are available through partnership with USVetServ. Two-year manufacturing warranty included. The device has FDA 510(k) clearance for USA use and is not yet available internationally.

Gereonics Inc. manufactures specialized biomedical sensors and electrodes for diagnostic and research applications. The company specializes in EEG (electroencephalography) electrodes and systems, including their proprietary Free-Cap EEG Net for non-invasive brain activity monitoring. Product portfolio includes biopotential electrodes for multi-channel physiological signal acquisition and piezoelectric respiratory sensors featuring low-cost, low-profile beltless/adhesive designs using PVDF technology. These sensors are used in sleep studies, clinical diagnostics, and research settings. The company serves hospitals, sleep laboratories, research institutions, and clinical facilities requiring portable and reliable signal acquisition devices. Manufacturing capabilities include custom electrode designs and respiratory sensor configurations. Gereonics operates as a US-based medical device supplier with distribution to clinical and research markets. Products are designed for ease of use, patient comfort, and accurate signal fidelity in demanding diagnostic environments.